Seminars in Pediatric Surgery
Volume 14, Issue 2 , Pages 111-117 , May 2005

Polycystic ovary syndrome in adolescent girls

  • Samantha M. Pfeifer, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Samantha M. Pfeifer, MD, University of Pennsylvania School of Medicine, Division of Reproductive Endocrinology and Infertility, Suite 800, 3701 Market Street, Philadelphia, PA 19104.

References 

  1. Dunaif A . Insulin resistance and the polycystic ovary syndrome (mechanism and implications for pathogenesis) . Endocr Rev . 1997;18:774–800
  2. Azziz R , Woods KS , Reyna R , et al.   The prevalence and features of the polycystic ovary syndrome in an unselected population . J Clin Endocrinol Metab . 2004;89:2745–2749
  3. Waldstreicher J , Santoro NF , Hall JE , et al.   Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease (indirect evidence for partial gonadotroph desensitization) . J Clin Endocrinol Metab . 1988;66:165–172
  4. Apter D , Butzow T , Laughlin GA , et al.   Accelerated 24 h luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism (relevance to the developmental phase of polycystic ovarian disease) . J Clin Endocrinol Metab . 1994;79:99–125
  5. Apter D , Butzow T , Laughlin GA , et al.   Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism . J Pediatr Endocrinol Metab . 1995;80:2966–2973
  6. Azziz R . We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome . Fertil Steril . 2003;80:264–265
  7. Dunaif A . Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome . Fertil Steril . 2003;80:262–263
  8. Dunaif A , Segal KR , Futterweit W , et al.   Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome . Diabetes . 1989;38:1165–1174
  9. Dunaif A , Xia J , Book CB , et al.   Excessive insulin receptor phosphorylation in cultured fibroblast and skeletal muscle . J Clin Invest . 1995;96:801–810
  10. Zhang L , Rodriguez H , Ohno S , et al.   Serine phosphorylation of human P450c17 increases 17,20-lyase activity (implications for adrenarche and the polycystic ovary syndrome) . Proc Natl Acad Sci . 1995;92:10619–10623
  11. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome . Fertil Steril . 2004;81:19–25
  12. van Hooff MHA , Voorhorst FJ , Kaptein MBH , et al.   Relationship of the menstrual cycle pattern in 14–17 year old adolescents with gynaecological age, body mass index and historical parameters . Hum Reprod . 1998;13:2252–2260
  13. Ibanez L , Potau N , Zampolli M , et al.   Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism . J Clin Endocrinol Metab . 1996;81:1237–1243
  14. Timpatanapong P , Rojanasakul A . Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne . J Dermatol . 1997;24:223–229
  15. Slayden SM , Moran C , Sams WM , et al.   Hyperandrogenemia in patients presenting with acne . Fertil Steril . 2001;75:889–892
  16. van Hooff MHA , Voorhorst FJ , Kaptein MBH , et al.   Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin . Fertil Steril . 2000;74:49–58
  17. Gadir A , Khatim MS , Mowafi RS , et al.   Implications of ultrasonically diagnosed polycystic ovaries (I. Correlations with basal hormonal profiles) . Hum Reprod . 1992;7:453–457
  18. Oppenheimer E , Linder B , Dimartino-Nardi J . Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans . J Clin Endocrinol Metab . 1995;80:614–618
  19. Dramusic V , Goh VHH , Rajan U , et al.   Clinical, endocrinologic, and ultrasound features of polycystic ovary syndrome in Singaporean adolescents . J Pediatr Adolesc Gynecol . 1997;10:125
  20. Azziz R . The time has come to simplify the evaluation of the hirsute patient . Fertil Steril . 2000;74:870–872
  21. Silfen ME , Denburg MR , Manibo AM , et al.   Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS) (comparison between non-obese and obese adolescents) . J Clin Endocrinol Metab . 2003;88:4682–4688
  22. Legro RS , Finegood D , Dunaif A . A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome . J Clin Endocrinol Metab . 1998;83:2694–2698
  23. Legro RS . Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome . J Pediatr Endocrinol Metab . 2002;15:1367–1378
  24. Legro RS , Kunselman AR , Dodson WC , et al.   Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome (a prospective, controlled study in 254 affected women) . J Clin Endocrinol Metab . 1999;84:165–169
  25. Palmert MR , Gordon CM , Kartashov AI , et al.   Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome . J Clin Endocrinol Metab . 2002;87:1017–1023
  26. Knowler WC , Barrett-Connor E , Fowler SE , et al.   Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med . 2002;346:393–403
  27. Dahlgreen E , Janson PO , Johansson S , et al.   Polycystic ovary syndrome and risk for myocardial infarction (evaluated from a risk factor model based on a prospective study of women) . Acta Obstet Gynecol Scand . 1992;71:599–604
  28. Ehrmann DA , Barnes RB , Rosenfeld RL , et al.   Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome . Diabetes Care . 1999;22:141–146
  29. Wild S , Pierpoint T , McKeigue P , et al.   Cardiovascular disease in women with polycystic ovary syndrome at long term follow-up (a retrospective cohort study) . Clin Endocrinol . 2000;52:595–600
  30. Talbott E , Guzick D , Clerici A , et al.   Coronary risk factors in women with polycystic ovary syndrome . Arterioscler Thromb Vasc Biol . 1995;15:821–826
  31. Pierpoint T , McKeigue M , Isaacs AJ , et al.   Mortality of women with polycystic ovary syndrome at long term follow-up . J Clin Epidemiol . 1998;51:581–586
  32. Kiddy DS , Hamilton-Fairley D , Bush A , et al.   Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome . Clin Endocrinol (Oxf) . 1992;36:105–111
  33. Clark AM , Thornley B , Tomlinson L , et al.   Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment . Hum Reprod . 1998;13:1502–1505
  34. Huber-Buchholz MM , Carey DGP , Norman RJ . Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome (role of insulin sensitivity and luteinizing hormone) . J Clin Endocrinol Metab . 1999;84:1470–1474
  35. Bravata DM , Sanders L , Huang J , et al.   Efficacy and safety of low-carbohydrate diets (a systematic review) . JAMA . 2003;289:1837–1850
  36. Foster GD , Wyatt HR , Hill JO , et al.   A randomized trial of a low-carbohydrate diet for obesity . N Engl J Med . 2003;348:2082–2090
  37. Moran LJ , Noakes M , Clifton PM , et al.   Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome . J Clin Endocrinol Metab . 2003;88:812–819
  38. Korytkowski MT , Mokan M , Horwitz MJ , et al.   Metabolic effects of oral contraceptives in women with polycystic ovary syndrome . J Clin Endocrinol Metab . 1995;80:3327–3334
  39. Jung-Hoffmann C , Kuhl H . Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone . Am J Obstet Gynecol . 1987;156:199–203
  40. Burkman RT . The role of oral contraceptives in the treatment of hyperandrogenic disorders . Am J Med . 1995;98:130S–136S
  41. Moghetti P , Tosi F , Tosti A , et al.   Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism (a randomized double blind, placebo-controlled trial) . J Clin Endocrinol Metab . 2000;85:89–94
  42. Tartagni M , Schonauer LM , De Salvia MA , et al.   Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism . Fertil Steril . 2000;73:718–723
  43. Fleming R , Hopkinson ZE , Wallace AM , et al.   Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo controlled trial . J Clin Endocrinol Metab . 2002;87:569–574
  44. Glueck CJ , Wang P , Fontaine R , et al.   Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS) . J Adol Health . 2001;29:160–169
  45. Moghetti P , Castello R , Negri C , et al.   Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome (a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation) . J Clin Endocrinol Metab . 2000;85:139–146
  46. Lord JM , Flight IH , Norman RJ . Metformin in polycystic ovary syndrome (a systematic review and meta-analysis) . Br Med J . 2003;327:951–953
  47. Ganie MA , Khurana ML , Gulati M , et al.   Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome (an open-labeled study) . J Clin Endocrinol Metab . 2004;89:2756–2762
  48. Morin-Papunen LC , Vauhkonen I , Koivunen RM , et al.   Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome (a randomized study) . J Clin Endocrinol Metab . 2000;85:3161
  49. Morin-Papunen LC , Koivunen RM , Roukonen A , et al.   Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome . Fertil Steril . 1998;69:691–696
  50. Pasquali R , Gambineri A , Biscotti D , et al.   Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome . J Clin Endocrinol Metab . 2000;85:2767–2774
  51. Ibanez L , Ong K , Ferrer A , et al.   Low-dose flutamaide-metfomrin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents with ovarian hyperandrogenism . J Clin Endocrinol Metab . 2003;88:2600–2606

PII: S1055-8586(05)00013-2

doi: 10.1053/j.sempedsurg.2005.01.007

Seminars in Pediatric Surgery
Volume 14, Issue 2 , Pages 111-117 , May 2005

Article Tools